Click the blue “Link” button above to view the presentation.
Discover More
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
Abstract Effective clinical management of patients with cancer requires highly accurate diagnosis, precise therapy selection, and highly sensitive monitoring of disease burden. Caris Assure is… […]
A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors
Trastuzumab deruxtecan-nxki (T-DXd) was approved on April 5, 2024, by the US Food and Drug Administration for adults with unresectable or metastatic human epidermal growth… […]
